@article {WATANABE4699, author = {SATOSHI WATANABE and OU YAMAGUCHI and AI MASUMOTO and YURI MAENO and YOSUKE KAWASHIMA and OSAMU ISHIMOTO and SHUNICHI SUGAWARA and HIROHISA YOSHIZAWA and TOSHIAKI KIKUCHI and TOSHIHIRO NUKIWA and KUNIHIKO KOBAYASHI}, title = {Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs}, volume = {38}, number = {8}, pages = {4699--4704}, year = {2018}, doi = {10.21873/anticanres.12776}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) with carboplatin plus pemetrexed or bevacizumab. However, no analysis of afatinib with platinum-doublet chemotherapies has been performed. Patients and Methods: We evaluated the safety and antitumor efficacy of afatinib combined with carboplatin and pemetrexed in EGFR-mutated non-small-cell lung cancer (NSCLC) patients who progressed during first-generation EGFR-TKIs. Results: Ten patients received 20 or 30 mg/day afatinib with carboplatin (area under the curve, 5) and pemetrexed (500 mg/m2). Dose-limiting toxicities included delay of afatinib >=14 days, grade 3 diarrhea, grade 3 hypokalemia, grade 3 serum amylase increase and grade 4 thrombocytopenia. The recommended dose of afatinib was 20 mg/day in this combination therapy. Overall response rate was 30\% and median progression-free survival was 13.7 months. Conclusion: This is the first study to investigate the combination of afatinib, carboplatin and pemetrexed. At the recommended dose, this combination was well tolerated and had a good clinical efficacy.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/8/4699}, eprint = {https://ar.iiarjournals.org/content/38/8/4699.full.pdf}, journal = {Anticancer Research} }